IGC Pharma Advances Alzheimer’s Trial with Strategic Colombian Partnership

India Globalization Capital (IGC Pharma) is significantly expanding the clinical development of its Alzheimer’s drug candidate, IGC-AD1. The company has broadened its trial network by adding a prominent research center in Colombia, a move aimed at enhancing the genetic diversity of its study participants and accessing specialized biomarker expertise.

Key Trial Details and Recruitment Progress

The ongoing Phase 2 clinical investigation, known as the CALMA study, is evaluating IGC-AD1 for the treatment of agitation in Alzheimer’s dementia. This cannabinoid-based therapeutic is being tested in a randomized, double-blind, placebo-controlled trial design, the industry gold standard for assessing clinical efficacy.

Operational momentum continues, with patient recruitment approximately 70% complete as of February 2026. Company leadership has expressed confidence in maintaining this pace, targeting the full enrollment of participants by mid-2026. Following this milestone, the study database will be locked prior to the release of topline results.

Enhancing Data Validity Through Network Expansion

The recent addition of the Grupo de Neurociencias de Antioquia (GNA) in Colombia represents a strategic expansion of IGC Pharma’s clinical footprint. This research group is recognized for its work with genetically distinct Alzheimer’s populations. By incorporating this center, IGC Pharma’s active trial network now encompasses 23 centers across 26 sites in the United States, Canada, and Colombia.

Should investors sell immediately? Or is it worth buying India Globalization Capital?

The primary objective of this geographic and genetic diversification is to strengthen the validity of the eventual study data. A more varied genetic pool among participants helps ensure the findings are robust and potentially applicable to a broader patient demographic.

Financial Reporting and Pipeline Focus

Investor attention is also turning to the company’s forthcoming financial update. IGC Pharma is scheduled to report its quarterly results in mid-February. These figures will provide critical insight into how the company is allocating its capital resources to fund the Phase 2 trial and its international expansion efforts.

The financial outlook and valuation of IGC Pharma remain intrinsically linked to the progress of its IGC-AD1 pipeline. The clinical advancements and strategic partnerships are central to the company’s trajectory as it moves through this pivotal stage of development.